http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이승재,양동원,손영민,김범생,정용안,손형선,주라형 대한치매학회 2003 Dementia and Neurocognitive Disorders Vol.2 No.1
Background & Objectives:Transient global amnesia (TGA) is a clinical syndrome characterized by sudden memory loss of recent events, transient inability to retain new information, and retrograde amnesia in the absence of other neurological signs and symptoms, resolving within 24 hours. This study investigated alterations in regional cerebral blood flow (rCBF) in patients with TGA by using statistical parametric mapping 99 (SPM99). Methods:5 patients with TGA and 9 age-matched normal control subjects were evaluated. Tc-99m-ethyl cysteinate dimer (ECD) SPECT were performed within 1 to 4 days of the event to measure the regional CBF, and SPM99 were applied to the objective analysis of SPECT data between two groups. Follow-up ECD SPECT was done at 49 to 107 days (mean 76.8) after the previous SPECT to evaluate the long term changes of the regional CBF. Results:The SPM analysis of SPECT images revealed significantly decreased rCBF in the left superior temporal gyrus, the left parietal supramarginal gyrus and the left thalamus (corrected p=0.01) and increased CBF in the contralateral mirror regions in patients with TGA. Follow-up SPECT showed persistent rCBF changes in the same regions. Conclusions:We demonstrate decreased perfusion in the left cerebral hemisphere and increased perfusion in the right cerebral hemisphere in patients with TGA. This reciprocal change of rCBF might suggest that imbalanced neuronal activity between two hemispheres may be important in the pathogenesis of the TGA. Also, the abnormal rCBF changes appeared to last long after the complete recovery of clinical manifestation of TGA.
( Tae Hyung Kim ),( Yeon Seok Seo ),( Yoo Ra Lee ),( Han Ah Lee ),( Sun Young Yim ),( Young Sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyunggin An ),( Hyung Joon Yim ),( Jong Eun 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Acute kidney injury (AKI) is a common complication in cirrhotic patients, and also associated with increased mortality and development of complications including variceal bleeding, spontaneous bacterial peritonitis and encephalopathy. Currently, there are limitations to use serum creatinine to distinguish patients at high risk for AKI in patients with cirrhosis. We tried to elicit the association between levels of renal biomarkers including serum cystatin C and urine N-acetyl-β-D-glucosaminidase (NAG) and the prognosis of patients with decompensated cirrhosis. Methods: In 84 hospitalized patients with decompensated cirrhosis and without AKI at baseline, we identified serum creatinine, cystatin C, urine NAG levels and outcomes including AKI development and mortality. Results: During a median follow-up of 6.1 months, 17 patients experienced AKI and 21 patients died. In the AUC analysis for predicting the development of AKI within 6 months, those of serum Cr and cystatin C levels and urine NAG level were 0.562, 0.802, and 0.833, respectively. On multivariate Cox-regression analysis, AKI significantly occurred more frequently with higher serum cystatin C (HR, 21.168; P=0.010) and urine NAG levels (HR, 1.023; P<0.001). Patients significantly survived longer with lower serum cystatin C (HR, 0.273; P=0.003), urine NAG levels (HR, 0.983; P=0.001), and Child-Pugh scores (HR, 0.627; P=0.001). Patients with the serum cystatin C ³ 1.0 mg/L and urine NAG ³ 31 U/g urinary Cr (n=12) showed more AKI development (P<0.001) and higher mortality (P<0.001) than other patients on Kaplan-Meier plots. Conclusions: Serum cystatin C and urine NAG levels are strong predictors for AKI development and mortality in patients with decompensated cirrhosis. In addition, the use of urine NAG in conjunction with cystatin C may provide a more accurate prediction.
( Tae Hyung Kim ),( Soon Ho Um ),( Yoo Ra Lee ),( Han Ah Lee ),( Sun Young Yim ),( Young Sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Yeon Seok Seo ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Y 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Decompensation in patients with liver cirrhosis deteriorates the quality of life and reduces the survival sharply. It is well-known that treatment with nucleos(t)ide analogues can restore liver function, resolve the decompensation and reduce mortality in patients with hepatitis B virus (HBV) related cirrhosis. This study aimed to reveal the efficacy of entecavir and tenofovir, which are preferred as initial treatment for chronic hepatitis B, in patients with HBV-related decompensated cirrhosis Methods: Patients with HBV-related decompensated cirrhosis who received entecavir or tenofovir as the initial antiviral therapy were retrospectively identified. Patients with chronic kidney disease or coexisting malignancy, such as hepatocellular carcinoma, were excluded. The primary outcome was the compensation, defined as reduction of Child-Pugh-Turcotte (CTP) score to five. Results: A total of 251 patients were enrolled. Mean age was 53.6 ± 10.8 years and 147 patients (58.6%) were men. CTP grade C presented in 146 patiens (58.2%). During a median follow-up of 34.3 months, the compensation and death occurred in 153 and 71 patients, respectively. Kaplan-Meier plots showed that type of antiviral agents did not influence significantly on compensation (log-rank test, P=0.088) and survival (P=0.295). In multivariate Cox-regression analysis, the compensation significantly occurred more frequently with lower BMI (odds ratio [OR], 0.955; 95% confidence interval [CI], 0.918- 0.993; P=0.021), higher platelet count (OR, 1.006; 95% CI, 1.004-1.011; P<0.001), log value of serum AFP level (OR, 1.905; 95% CI, 1.486-2.443; P<0.001) and absense of ascites (OR, 1.762; 95% CI, 1.234-2.517; P=0.002). Conclusions: The effects on prognosis of HBV-related decompensated cirrhosis were comparable between entecavir and tenofovir. We identified four predictive factors including BMI, platelet count, serum AFP level and ascites for reversibility of decompensation in patients with HBV-related cirrhosis.
가미 태음조위탕과 저열량 식이를 병행한 체중 감량 프로그램에서 발생한 이상 반응 분석
윤나라(Na-Ra Yoon),유영재(Young-Jae Yoo),김민지(Min-ji Kim),김서영(Seo-Young Kim),임영우(Young-Woo Lim),임형호(Hyung Ho Lim),박영배(Young-Bae Park) 한방비만학회 2018 한방비만학회지 Vol.18 No.1
Objectives: The objective of this study was to assess the safety of Gamitaeeumjowee-tang by analyzing adverse events in weight loss program in combination with Gamitaeeumjoweetang and low-calorie diet. Methods: A retrospective review of adverse events in weight loss program in combination with Gamitaeeumjowee-tang and low-calorie diet from the electronic medical chart (n=124) between June 2015 and December 2016 was conducted. Three Korean Medicine Doctors (KMDs) reviewed adverse events for two times, during week 2 to 4 and at week 10, after starting weight loss program. Adverse events were evaluated in terms of causality, severity and system-organ classes. Also, agreement among the three KMDs was made through further discussion in case of disagreement after independent review. Results: The overall rate of adverse events was 37.1% during week 2 to 4 and 16.9% at week 10. For causality of adverse events using the World Health Organization-Uppsala Monitoring Centre causality categories, 52.2% were evaluated possible at week 2-4 and 57.1% were evaluated unlikely at week 10. All symptoms were evaluated as mild by LDS scale. Nausea (15, 12.1%) was the most frequent adverse event at week 2-4 and dizziness (6, 4.8%) was the most common at week 10. Conclusions: Adverse events decreased over time. There were no serious adverse events and none of the subjects were dropped due to adverse events. Continuous study is needed to prove the safety of Gamitaeeumjowee-tang for treating obesity.
( Han Ah Lee ),( Yoo Ra Lee ),( Tae Hyung Kim ),( Sun Young Yim ),( Young-sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Dong-sik Kim ),( Hyung Joon Yim ),( Jong Eun 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: This study compared the survival benefits between surgical resection and radiofrequency ablation (RFA) in single small hepatocellular carcinoma (HCC). Methods: Patients registered in the database of Korea central cancer registry for HCC between 2008 and 2014 who received surgical resection or RFA for a single HCC of maximum size 3cm were reviewed. The cumulative overall survival (OS) and retreatment-free survival (RFS) were compared according to the type of treatment. Results: A total of 1426 patients were included, 662 (46.4%) in the resection group and 764 (53.6%) in the RFA group. The 5-year OS rates were 91.8% for resection, and 84.9% for RFA, respectively (P<0.001). The 5-year RFS rates were 77.8% for the resection and 70.5% for RFA, respectively (P=0.002). In patients with maximum tumor size <2cm, there was no significant difference in 5-year OS rates between the two groups (91.8% for resection, and 87.5% for RFA, respectively; P=0.094), while resection was superior to RFA in the 5-year RFS rates (81.0% for resection, and 72.3% for RFA, respectively; P=0.017). Resection was superior in both 5-year OS and RFS rates in those with maximum tumor size ≥2cm and <3cm (91.9% for resection, and 80.2% for RFA, respectively; P<0.001; 76.2% for resection, and 67.2% for RFA, respectively; P=0.007). In the entire cohort, type of treatment (HR 1.457, P=0.032), age (HR 1.031, P<0.001), serum albumin (HR 0.466, P<0.001), and serum creatinine level (HR 1.282, P<0.001) were independently associated with survival. Type of treatment (HR 1.544, P<0.001) and maximum size of tumor (HR 1.353, P=0.002) were independent predictors of RFS. Conclusions: In patients with maximum tumor size <2cm, OS is comparable between resection and RFA groups, while RFS is better in resection group. Surgical resection is superior in both OS and RFS in patients with maximum tumor size ≥2cm and <3cm.
만성두통 환자에서 한방 치료 후 인영혈 부위의 뇌혈류에 대한 연구
이충식 ( Chung Sik Lee ),박보라 ( Bo Ra Park ),박인숙 ( In Suk Park ),김지훤 ( Ji Hwon Kim ),이상언 ( Sang Eon Lee ),임진영 ( Jin Young Lim ),류영수 ( Yeoung Su Lyu ),강형원 ( Hyung Won Kang ),김태헌 ( Tae Heon Kim ) 대한한방신경정신과학회 2009 동의신경정신과학회지 Vol.20 No.1
Objectives: This study was performed to change of blood flow in In-Young(ST9) after treatment on chronic daily headache patients. Methods: Monitoring of TCD was examined in 10`s chronic daily headache patients before and after treatment. Mean velocity flow, systolic velocity and pulsatility index were analyzed from TCD at In-Young(ST9). The patients was laid for 20 minutes before treatment and also for treatment. Results: The results showed a significant(p<0.05: Paired T-test) decrease in mean velocity flow and systolic velocity. but there were no significant differences in pulsatility index. Conclusions: These results suggest that there were significant change on blood flow in In-young of chronic daily headache patients.
Avenanthramide-C Restores Impaired Plasticity and Cognition in Alzheimer’s Disease Model Mice
Vijay Sankar Ramasamy,Manikandan Samidurai,Hyung Joon Park,Ming Wang,Ra Young Park,Seon Young Yu,Hee Kyung Kang,Semi Hong,Won-Seok Choi,Yu Young Lee,Hyung-Seok Kim,Jihoon Jo 한국식품영양과학회 2021 한국식품영양과학회 학술대회발표집 Vol.2021 No.10
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline and dementia with no effective treatment. Here, we investigated a novel compound from oats named avenanthramide-C (Avn-C), on AD-related memory impairment and behavioral deficits in transgenic mouse models. Acute hippocampal slices of wild-type or AD transgenic mice were treated with Avn-C in the presence or absence of oligomeric Aβ42. LTP analyses and immunoblotting were performed to assess the effect of Avn-C on Aβ-induced memory impairment. To further investigate the effect of Avn-C on impaired memory and Aβ pathology, two different AD transgenic mice (Tg2576 and 5XFAD) models were orally treated with either Avn-C or vehicle for 2 weeks. They were then assessed for the effect of the treatment on neuropathologies and behavioral impairments. Avn-C reversed impaired LTP in both ex vivo- and in vivo-treated AD mice hippocampus. Oral administration (6 mg/kg per day) for 2 weeks in AD mice leads to improved recognition and spatial memory, reduced caspase-3 cleavage, reversed neuroinflammation, and to accelerated glycogen synthase kinase-3β (pS9GSK-3β) and interleukin (IL-10) levels. Avn-C exerts its beneficial effects by binding to α1A adrenergic receptors to stimulate adenosine monophosphate-activated kinase (AMPK). All of the beneficial effects of Avn-C on LTP retrieval could be blocked by prazosin hydrochloride, a specific inhibitor of α1A adrenergic receptors. Our findings provide evidence, for the first time, that oats’ Avn-C reverses the AD-related memory and behavioral impairments, and establish it as a potential candidate for Alzheimer’s disease drug development.